BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bio Based Press - ECPv5.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bio Based Press
X-ORIGINAL-URL:https://www.biobasedpress.eu/nl/
X-WR-CALDESC:Evenementen voor Bio Based Press
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20190611T080000
DTEND;TZID=Europe/Paris:20190612T170000
DTSTAMP:20201230T222203
CREATED:20190425T152454Z
LAST-MODIFIED:20190425T152454Z
UID:14986-1560240000-1560358800@www.biobasedpress.eu
SUMMARY:13th Biosimilars Congregation
DESCRIPTION:The development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020. The global biosimilar market is estimated to register a CAGR of 39.53% over the forecast period of 2017-2023. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs. By 2018\, biologics worth more than US$68 billion annual sales will lose patent protection. Due to structural complexity of the biosimilar drugs\, multi-layered manufacturing and risk of immunogenicity\, separate regulatory pathways have been drafted to introduce them into the market. Increasing investment by the companies for the development of biosimilars will also be the key factor driving the market. \nOur 13th Biosimilars Congregation 2019 will provide insight into the current state of play in the EU and stimulate debate\, in a multi-stakeholder setting\, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies\,  our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe\, Biosimilar products to the market place. By attending this conference\, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.
URL:https://www.biobasedpress.eu/nl/event/13th-biosimilars-congregation/
LOCATION:London
END:VEVENT
END:VCALENDAR